"Our research builds on the body of knowledge for the role of an agent which activates the full IL-15 biology pathway in the field of cell therapy," said
The oral presentation will be virtually live streamed on
Key details and takeaways from the two collaborator presentations include:
Abstract 27: "Targeting Ewing sarcoma, Osteosarcoma and Neuroblastoma with Anti-MCAM Chimeric Antigen Receptor Modified Natural Killer Cells" Luo, W., et al.
Presentation Type: Oral Presentation
Presenting Author: Wen Luo, Ph.D.
Session: Oral Abstract - Session C - Immune and Gene Therapy
Virtual Live Stream of the presentation will begin at
- NKTR-255 enhances expression of NK cell-activating receptors, stimulates NK cell proliferation and sustains NK cell expansion
- NKTR-255 enhances anti-MCAM CAR NK cell cytotoxicity against Ewing sarcoma, osteosarcoma and neuroblastoma in vitro
- Anti-MCAM CAR NK alone or in combination with NKTR-255 significantly decrease lung metastasis and prolong animal survival in an Ewing sarcoma orthotopic mouse model
Abstract 201: "Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell- Mediated Cytotoxicity Combined with anti-CD20 or anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL)" Chu, Y., et al.
Presentation Type: Poster
- NKTR-255 + obinutuzumab, a humanized type II anti-CD20 monoclonal antibody (mAb) glycoengineered to enhance Fc receptor affinity, significantly enhanced the in vitro cytotoxicity of anti-CD19 CAR NK compared to controls against multiple
Burkittlymphoma model (Raji) (p<0.0081) as well as release of perforin (p<0.05), IFN-g (p<0.001) and granzyme B (p<0.01)
- These results were further confirmed utilizing Raji-2R and Raji-4RH cells
- NKTR-255 + polatuzumab vedotin (PV), an anti-CD79 mAb glycoengineered to enhance Fc receptor affinity, significantly enhanced the in vitro cytotoxicity of anti-CD19 CAR NK cells compared to control groups such as expanded NK cells +NKTR-255 + PV against Raji (p<0.0001), Raji-2R (p<0.0003), and Raji-4RH (p<0.0311), as well as enhanced release of Interferon gamma (IFN-γ) and perforin
Posters will be on display Sunday, April 24, 2022 from
Poster Receptions are on
Founded in 1860,
NKTR-255 is an investigational IL‐15 receptor agonist designed to boost the immune system's natural ability to fight cancer. NKTR-255 increases the proliferation and survival of cancer-killing natural killer (NK) cells and memory CD8+ T cells. NKTR-255 engages the entire IL-15 receptor complex (IL‐15Rα/IL‐15Rβγ) to enhance the formation of long-term immunological memory, which may lead to sustained antitumor immune response.
NKTR-255 is specifically engineered using Nektar's expertise in polymer chemistry to mimic the natural biological activity of the body's own IL-15, resulting in optimal activation of the IL-15 pathway. NKTR-255 is uniquely designed to overcome the challenges of recombinant IL-15, which has to be given in high doses due to rapid clearance from the body, limiting its utility due to toxicity and lack of convenience and use.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: "will," "may," "design," "potential," "initiate," "plan," "advance" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the future development plans and the timing of data readouts for bempegaldesleukin. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of bempegaldesleukin are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) bempegaldesleukin is an investigational agent and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in ongoing clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) bempegaldesleukin remains in clinical development and the risk of clinical failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the end of clinical trials and the availability of clinical data may be delayed or unsuccessful due; (v) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the
a) MCAM: Melanoma Cell Adhesion Molecule
b) CAR: Chimeric Antigen Receptor
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-and-collaborators-present-preclinical-data-on-nktr-255-a-novel-il-15-receptor-agonist-in-combination-with-car-cell-therapies-at-the-2022-tandem-meetings--transplantation--cellular-therapy-meetings-of-astct-and-cibmtr-301531360.html